1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004; 350: 1118-1129.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
3. Lau GK1, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-2695.
4. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepat. 2001; 8: 311-321.
5. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med. 1991; 324: 1699-1704.
6. Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology. 1999; 29: 1252-1258.
7. Akahane Y, Yamanaka T, Suzuki H, Sugai Y, Tsuda F, Yotsumoto S, Omi S, Okamoto H, Miyakawa Y, Mayumi M. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology. 1990; 99: 1113-1119.
8. Brunetto MR1, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, Saracco G, Verme G, Will H. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A. 1991; 88: 4186-4190.
9. Carman WF1, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989; 2: 588-591.
10. Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R, Guardia J. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology. 1995; 22: 1641-1647.
11. Grandjacques C1, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, Trépo C, Zoulim F. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol. 2000; 33: 430-439.
12. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, Miyakawa Y, Mayumi M. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 994; 68: 8102-8110.
13. Hunt CM1, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31: 1037-1044.
14. European Association for the Study of the Liver (EASL) Guidelines: Journal of Hepatology 2009; 50: 227-242.
15. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M; Asian-Pacific consensus update working party on chronic hepatitis B: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update 2005: 25: 472-489.
16. Marcellin P1, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HbeAgnegative chronic hepatitis B, N Engl J Med 2004;351:1206-1217.
17. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303.
18. Bonino F1, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007; 56: 699-705.
19. Tekeli A. Hepatit B virüsünde mutasyon ve önemi. Tabak F, Balık İ, Tekeli E, ed. Viral Hepatit 2005’te. Ankara: Viral Hepatitle Savaşım Derneği. 2005; s:160-168.
20. Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: Clinical characteristics and correlation with the course of HBeAg-to-AntiHBe seroconversion. J Clin Microbiol 2002; 40: 16-21.
21. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 125-137.
22. Seo Y, Yoon S, Hamano K, Nakaji M, Yano Y, Katayama M, Ninomiya T, Hayashi Y, Kasuga M. Response to interferonalpha in chronic hepatitis B with and without precore mutant strain detected by mutation site-specifi c assay. J Clin Gastroenterol 2004; 38: 460-464.
23. Arslan U, Tuncer İ, Fındık D, Ural O. HBeAg negatif, anti-HBe pozitif kronik hepatit B olgularında prekor/kor bölge mutasyonlarının ve genotip dağılımlarının değerlendirilmesi. İnfeksiyon dergisi 2008; 22:123-129.
24. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol. 1996; 70: 5845-5851.
25. Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2012; 56: 67-75.
26. Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology. 1997; 233: 374-381.
27. Yoo BC, Park JW, Kim HJ, Lee DH, Cha YJ, Park SM. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. J Hepatol. 2003; 38: 98-103.
28. Pang A, Yuen MF, Yuan HJ, Lai CL, Kwong YL. Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis E antigen seroconversion. J Hepatol. 2004; 40: 1008-1017.
29. Chen WN, Oon CJ. Mutations and deletions in core promoter and precore stop codon in relation to viral replication and liver damage in Singaporean hepatitis B virus carriers. Eur J Clin Invest. 2000; 30: 787-792.
30. Jammeh S, Tavner F, Watson R, Thomas HC, Karayiannis P. Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J Gen Virol. 2008; 89: 901-909.
31. Agdamag DM1, Kageyama S, Leaño PS, Solante RM, Telan EF, Que ER, Ichimura H. Prediction of response to treatment of chronic hepatitis B with pegylated interferon in the Philippines. Med Virol. 2010; 82: 213-219.
32. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol. 2009; 46: 117-123.